SEEDSUPPLY
Delivering High-Throughput Screening

There has always been intense pressure within the pharmaceutical market to deploy advanced screening technologies in order to maximize their drug discovery research capabilities and accelerate the delivery of high-quality drugs to patients quickly. Despite the traditional high throughput screening technology gaining widespread popularity over the last two decades, it still had limitations related to screening thousands of extra-and intracellular molecular non-tractable targets. To accelerate the drug discovery process, a much-advanced drug discovery technology is needed that can not only search for molecules with the potential to bind and modulate the function of a particular target but also improve the drug discovery speed.

This is where SEEDSUPPLY, a Japan-based drug research, and development firm, steps in with its industry-first services and state-of-theart binder selection technology. “Our ultimate mission is to contribute to the effective progress in drug discovery research of small molecule compounds and improve the speed of drug discovery,” says Naoki Tarui, Ph.D., CEO of SEEDSUPPLY.

SEEDSUPPLY’s binder selection technology effectively explores compounds against drug targets with high sensitivity and convenience. The screening can be used for any type of target, as not only purified proteins, but also membrane fractions and microsomal fractions can be used.

Through this novel technology, the company performs screening for compounds that are bound to a protein from a library of 400,000 compounds. The company also performs screening for proteins that are bound to compounds from a library of 18,000 proteins. This technology gives a great advantage to the clients as they can perform the screening without having to chemically modify the compound or immobilize the protein.

“Our technology is first of its kind that effectively detects the binding protein of compounds whose target molecule is unknown,” states Tarui. Using this technology wherein the binding activity is the index, organizations can obtain a binding protein of compound for which biochemical activity measurement is difficult, such as scaffold protein, ion channel, transporter, or orphan receptor.

SEEDSUPPLY also supports the screening of binding proteins using the clients’ compound libraries. By using Binder Selection Technology as a hub, it becomes easier to proceed with library sharing, and as a result, it will improve in-house drug discovery capabilities.

Another important aspect of this novel technology is that it enabled SEEDSUPPLY to acquire a binding compound for a certain transcription factor drug targets that were difficult to construct with the traditional High Throughput screening. These compounds were evaluated in several low-throughput cell assays and confirmed the desired anti-cancer activity.

An exceptionally bright future awaits SEEDSUPPLY as they are already witnessing a widespread adoption of its technology and screening services. Having the binding compound libraries for several types of GPCRs and transporters, the company will be able to provide binding compounds immediately upon requests from the clients. In the future, the company also aims to increase its drug target portfolio to deliver the binding compound to clients faster.